NervGen Pharma Reports 2025 Results, Updates

NervGen Pharma has released its full-year 2025 financial results and provided key business updates, including a completed End-of-Phase 2 meeting with the FDA. The company anticipates a regulatory update in early Q2 2026 and remains on track to initiate Phase 3 trials. These developments indicate significant progress in the company's drug development pipeline, particularly for its neurological treatments. The positive trajectory suggests potential for future breakthroughs and market entry, reflecting a promising outlook for NervGen Pharma's research endeavors.